Orthofix Medical Inc. (NASDAQ:OFIX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Orthofix Medical Inc. (NASDAQ:OFIX) have earned an average recommendation of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $21.75.

OFIX has been the topic of several research analyst reports. Wall Street Zen upgraded Orthofix Medical from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Orthofix Medical in a research note on Saturday, September 27th. Finally, Barrington Research reaffirmed an “outperform” rating and issued a $17.00 price objective on shares of Orthofix Medical in a research report on Tuesday, September 23rd.

Orthofix Medical Stock Up 2.8%

NASDAQ:OFIX opened at $14.61 on Wednesday. The company’s 50-day simple moving average is $13.99 and its 200-day simple moving average is $12.98. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.50 and a current ratio of 2.67. Orthofix Medical has a fifty-two week low of $10.24 and a fifty-two week high of $20.73. The stock has a market capitalization of $576.95 million, a P/E ratio of -4.61 and a beta of 0.89.

Orthofix Medical (NASDAQ:OFIX) last posted its earnings results on Tuesday, August 5th. The medical device company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.40). Orthofix Medical had a negative net margin of 15.29% and a negative return on equity of 25.43%. The firm had revenue of $203.12 million for the quarter, compared to analysts’ expectations of $196.89 million. Orthofix Medical has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Orthofix Medical will post -2.81 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Orthofix Medical

Hedge funds have recently made changes to their positions in the company. Paradigm Capital Management Inc. NY raised its stake in Orthofix Medical by 34.6% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 3,340,600 shares of the medical device company’s stock worth $37,248,000 after acquiring an additional 858,900 shares during the last quarter. Bank of America Corp DE lifted its stake in Orthofix Medical by 659.5% during the 2nd quarter. Bank of America Corp DE now owns 687,410 shares of the medical device company’s stock valued at $7,665,000 after acquiring an additional 596,907 shares during the period. Engine Capital Management LP boosted its holdings in shares of Orthofix Medical by 13.6% in the 2nd quarter. Engine Capital Management LP now owns 4,251,671 shares of the medical device company’s stock valued at $47,406,000 after acquiring an additional 510,281 shares during the last quarter. AYAL Capital Advisors Ltd increased its stake in shares of Orthofix Medical by 74.7% in the second quarter. AYAL Capital Advisors Ltd now owns 943,203 shares of the medical device company’s stock worth $10,517,000 after acquiring an additional 403,433 shares during the period. Finally, Philosophy Capital Management LLC acquired a new stake in shares of Orthofix Medical in the first quarter worth $6,047,000. 89.76% of the stock is owned by institutional investors and hedge funds.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.